First and Next Generation Native rFVIII in the Treatment of Hemophilia A. What Has Been Achieved? Can Patients be Switched Safely?

ABSTRACT

The introduction of plasma-derived human factor VIII (FVIII) and later human recombinant FVIII (rFVIII) has potentially allowed patients suffering from hemophilia A to have a quality of life and life expectancy similar to the population at large. One of the major achievements in molecular biology over the past 15 years was the sequencing of the gene coding for FVIII, leading eventually to the ability to isolate the human gene for FVIII and transfect cells to produce human rFVIII. The first rFVIII products, which are native full-length FVIII molecules, have proved to have an excellent efficacy and safety profile in patients with hemophilia A. Initial concerns about a potential increased inhibitor formation have not been confirmed so far but long-term pharmacovigilance of inhibitor formation is still ongoing. To date, no transmission of hepatitis or human immunodeficiency virus (HIV) attributable to rFVIII products has been reported. However, a theoretical risk of transmission of infectious disease does exist as long as nonsynthetic proteins are used during the production process. The next-generation native rFVIII has been developed to minimize the exposure of patients to animal or human plasma-derived proteins. This has been achieved through major changes to the process of production of rFVIII from baby hamster kidney cells (BHK). This change has included the introduction of a solvent/detergent step and, of more importance, the introduction of a purification procedure without using albumin as a stabilizer. Finally, the rFVIII (BHK) is formulated using sucrose as the final stabilizer to produce the sucrose formulated rFVIII referred to as rFVIII-FS. This article summarizes the recently published pharmacokinetic, safety, and efficacy data for the native rFVIII-FS and compares its clinical profile with that of the first-generation rFVIII.

KEYWORDS

Hemophilia A - rFVIII - sucrose-formulated recombinant FVIII - review - clinical trials

REFERENCES

• 1 Levine P H. Efficacy of self-therapy in hemophilia: a study of 72 patients with hemophilia A and B.  N Engl J Med . 1974;  291 1381-1384
• 2 Aledort L M. Lessons from hemophilia.  N Engl J Med . 1982;  306 607-608
• 3 Rizza C R, Spooner R JD. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-1980; report on behalf of the directors of haemophilia centres in the United Kingdom.  BMJ . 1983;  286 929-933
• 4 Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H. Experiences with recombinant factor VIII products: Development of inhibitors and immune tolerance therapy.  Ann Hematol . 1998;  76 A1-A6
• 5 Beauvais P, Billette de Villemeur T. Prion diseases and blood transfusion.  Transfus Clin Biol . 1999;  6 24-28
• 6 Abshire T C, Brackmann H H, Scharrer I. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy.  Thromb Haemost . 2000;  83 811-816
• 7 Aygoren-Pursun E, Scharrrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. The German Kogenate Study Group.  Thromb Haemost . 1997;  78 1352-1356
• 8 Seremetis J, Lusher J M, Abildgaard C F. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy.  Haemophilia . 1999;  5 9-16
• 9 Lusher J M, Arkin S, Abildgaard C F, Schwartz R S. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. The Kogenate Previously Untreated Patient Study Group.  N Engl J Med . 1993;  328 453-459
• 10 Lusher J, Arkin S, Abildgaard C F, Hurst D. Recombinant FVIII (Kogenate) treatment for previously untreated patients (PUPs) with hemophilia A: update on the safety and efficacy and inhibitor development after seven study years(Abst PD-664).  Thromb Haemost . 1997;  78(Suppl 1) 162-163
• 11 Kreuz W, Manco-Johnson M, Gazengel C. Recombinant FVIII formulated with sucrose (rFVIII-FS) is safe and efficacious in pediatric patients with hemophilia A (Abst).  Blood . 2000;  96 226A
• 12 Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer J, Gunger T, Kornhuber B. Epidemiology of inhibitors in haemophilia A.  Vox Sang . 1996;  70 2-8
• 13 Ehrenforth S, Kreuz W, Scharrer I, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophilics.  Lancet . 1992;  342 594-598
• 14 White B, Cotter M, Bryne M, O'Shea E, Smith O P. High responding factor VIII inhibitors in mild haemophilia-is there a link with recent changes in clinical practices?.  Haemophilia . 2000;  6 113-115
• 15 Sultan Y, and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France.  Thromb Haemost . 1992;  67 600-602
• 16 Scharrer I, Bray G L, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates.  Haemophilia . 1999;  5 145-154
• 17 Scharrer I, Brackmann H H, Sultan Y. Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A.  Haemophilia . 2000;  6 614-618
• 18 Brackmann H H, Gormsen J. Massive factor VIII infusion in hemophiliacs with factor VIII inhibitors, high responder.  Lancet . 1977;  2 933
• 19 Kreuz W, Ehrenforth S, Funk M. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 year follow-up.  Haemophilia . 1995;  1 24-32
• 20 Kreuz W, Becker S, Lenz E. Factor VIII inhibitors in patients with hemophilia A: Epidemiology of inhibitor development and induction of immune tolerance for factor VIII.  Semin Thromb Hemost . 1995;  21 382-389
• 21 Mauser-Bunschoten P, Nieeuwenhuis K, Rosendaal G, Van der Berg M. Low dose immune tolerance induction in hemophilia A patients with inhibitors.  Blood . 1995;  86 983-988
• 22 Batlle J, Lopez M F, Brackmann H H. Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors.  Haemophilia . 1999;  5 431-435
• 23 Unuvar A, Warrier J, Lusher J M. Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.  Haemophilia . 2000;  6 150-157
• 24 Morfini M, Messori A, Longo G. Factor VIII pharmacokinetics: intermittent infusions versus continuous infusions.  Blood Coagul Fibrinolysis . 1996;  7 S27-S33
• 25 Hathaway W E, Christian M J, Clark S L, Hasiba U. Comparison of continuous infusion of factor VIII concentrate therapy in hemophilia A.  Am J Hematol . 1984;  17 85-88
• 26 Bona R D, Weistein R A, Weisman S J, Barrolomea A, Rickles F R. The use of continuous infusion of factor concentrates in the treatment of hemophilia.  Am J Hematol . 1989;  32 8-13
• 27 Hurst D, Zabor S, Malianni D, Millar D. Evaluation of recombinant factor VIII (Kogenate®) stability for continuous infusion using a minipump infusion device.  Haemophilia . 1998;  4 785-789
• 28 Donna M M, Woloschuk P T, Heather A E. In vitro stability of recombinant factor VIII formulated with sucrose (Abst).  Blood . 1999;  94 3709
• 29 Donna M M, Woloschuk P T, Heather A E. In vitro stability of recombinant factor VIII (Kogenate-SF) stored in an ambulatory micro-infuser device (Abst).  Blood . 2000;  96 4021
• 30 Lusher J M, Petrini P, Angiolillo A. Antibody and inhibitor patterns in previously untreated patients (PUPs) treated exclusively with B-domain deleted recombinant factor VIII (BDDrFVIII) (Abst).  Blood . 2000;  96 1144